Day: September 19, 2020

MEDIA AVAILABILITY: CN Police officers available for media interviews during Rail Safety Week

HOMEWOOD, Ill., Sept. 19, 2020 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) is offering members of the media the opportunity to talk with uniformed police officers during Rail Safety Week, from September 21-27, about the importance of rail safety at crossings and the dangers of trespassing.Members of the CN Police Service will be available for media interviews throughout the week. Providing that social distancing be respected or in a virtual manner, we invite media outlets to contact CN to arrange onsite, in studio or on air interviews. The CN media relations team is also happy to offer visual elements for on camera interviews.CN will mark Rail Safety Week with a public awareness campaign aimed at reducing the number of collisions and trespassing-related accidents. Throughout the week, CN Police will conduct safety initiatives at...

Continue reading

MEDIA AVAILABILITY: CN Police officers available for media interviews during Rail Safety Week

MONTREAL, Sept. 19, 2020 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) is offering members of the media the opportunity to talk with uniformed police officers during Rail Safety Week, from September 21-27, about the importance of rail safety at crossings and the dangers of trespassing.Members of the CN Police Service will be available for media interviews throughout the week. Providing that social distancing be respected or in a virtual manner, we invite media outlets to contact CN to arrange onsite, in studio or on air interviews. The CN media relations team is also happy to offer visual elements for on camera interviews.CN will mark Rail Safety Week with a public awareness campaign aimed at reducing the number of collisions and trespassing-related accidents. Throughout the week, CN Police will conduct safety initiatives at commuter...

Continue reading

DISPONIBILITÉ POUR LES MÉDIAS : Des agents de la Police du CN seront disponibles pour donner des entrevues pendant la Semaine de la sécurité ferroviaire 2020

MONTRÉAL, 19 sept. 2020 (GLOBE NEWSWIRE) — Le CN (TSX : CNR) (NYSE : CNI) offre aux médias la possibilité de s’entretenir avec des agents de police en uniforme à propos l’importance de la sécurité ferroviaire aux passages à niveau ainsi que des dangers liés aux intrusions pendant la Semaine de la sécurité ferroviaire, qui se tiendra du 21 au 27 septembre.Des membres de la Police du CN seront disponibles pour donner des entrevues aux médias pendant toute la semaine. Nous invitons donc les médias à communiquer avec le CN pour planifier des entrevues sur place, en studio ou en ondes, à la condition que les règles de distanciation soient respectées ou que les rencontres soient virtuelles. L’équipe de relations avec les médias du CN sera également heureuse de fournir des éléments visuels pour les entrevues filmées.Le CN marquera le coup...

Continue reading

Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)sBLA submission for accelerated approval expected in fourth quarter 2020, pending FDA final guidancePhase 3 TROPiCS-04 study in third-line mUC underwayCompany to host conference call and webcast today at 2:00 p.m. Eastern TimeMORRIS PLAINS, N.J., Sept. 19, 2020 (GLOBE NEWSWIRE) — Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced positive results from cohort 1 of cisplatin-eligible patients in the pivotal Phase 2 TROPHY U-01 study of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC). Results confirm the interim findings and prior...

Continue reading

Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapyTrodelvy is the first ADC to significantly improve OS in metastatic triple-negative breast cancer (mTNBC)sBLA for full approval to be submitted in fourth quarter 2020 under RTOR processCompany to host conference call and webcast today at 2:00 p.m. Eastern TimeMORRIS PLAINS, N.J., Sept. 19, 2020 (GLOBE NEWSWIRE) — Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that results from the confirmatory Phase 3 ASCENT study showed that Trodelvy (sacituzumab govitecan-hziy) significantly extended overall survival (OS) and improved overall response rate (ORR)...

Continue reading

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in patients with lung or liver metastases, which are observed in 41% of postmenopausal women with HR+ aBC, and considered more aggressive and challenging to treat1-3  Data add to growing body of evidence for Piqray, the first and only treatment specifically approved for aBC with a PIK3CA mutation Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvestrant, compared to fulvestrant alone, in hormone receptor positive, human...

Continue reading

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapyFinal overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours expressed PD-L1 and who received Tecentriq plus nab-paclitaxelResults from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel for the treatment of people with metastatic TNBC and whose tumours expressed PD-L1, did not meet its primary endpoint of progression-free survivalBasel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase...

Continue reading

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the COMBI-i clinical trial despite the study not meeting the primary endpoint for the investigational triplet therapy Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agentsBasel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared...

Continue reading

Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer

The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress, demonstrates that niraparib maintenance treatment resulted in a 68% reduction in the risk of disease progression or death in the overall study population when compared to placebo.An individualized starting dose regimen based on patient’s baseline weight and/or platelet count shown to be effective; lower rates of hematological adverse events were observed with the individualized dosing group.SHANGHAI and SAN FRANCISCO, Sept. 19, 2020 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced detailed positive results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled study of ZEJULA (niraparib) as a maintenance...

Continue reading

Blockchain Distributed Ledger Market Key Company Analysis, 2020-2027

According to a new report published by Allied Market Research, titled,”Blockchain Distributed Ledger Market by Type and End User: Global Opportunity Analysis and Industry Forecast, 2017 – 2023,”the global blockchain distributed ledger market accounted for $228 million in 2016, and is expected to reach $5,430 million by 2023, growing at a CAGR of 57.6% from 2017 to 2023. North America dominated the global market in terms of revenue in 2016, accounting for more than 40% share of the global market, followed by Europe. Negligible fees for transaction in blockchain distributed ledger applications, elimination of third parties in business deals, and less chances of fraud & identity theft are the key drivers of the global blockchain distributed ledger market. Also, better security measurements, improved capital optimization,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.